Theratechnologies Named Recipient of the 2021 ADRIQ Innovation Award in the "Life Sciences" Category

Rhea-AI Summary

Theratechnologies Inc. (THTX) has won the 2021 Innovation Award in the Life Sciences category at the ADRIQ Innovation Awards Gala held on November 25, 2021. This recognition highlights the company's leadership in innovation within Quebec. Earlier in 2021, THTX received the FDA's Fast-track designation for TH1902, a promising drug targeting advanced solid tumors. The Canadian Cancer Society and the Government of Quebec are supporting THTX's research with a funding commitment of $1.4 million.

Positive

• Awarded the 2021 Innovation Award at the ADRIQ gala, enhancing corporate reputation.
• FDA's Fast-track designation for TH1902 indicates strong potential for the drug's development.

Negative

• None.

MONTREAL, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, is pleased to announce that it was awarded of the 2021 Innovation Award in the “Life Sciences” category at the 31st ADRIQ Innovation Awards Gala held on November 25, 2021.

Every year, the ADRIQ (Association pour le développement de la recherche et de l'innovation du Québec) gala rewards Quebec-based companies for leadership in innovation in their respective field.

At the beginning of 2021, Theratechnologies received the United States Food and Drug Administration's "Fast-track" designation for TH1902 as a single agent for the treatment of patients with advanced and recurrent solid tumors expressing the sortilin receptor and refractory to standard treatments. TH1902 is the lead peptide-drug conjugate derived from the SORT1+ Technology™ in oncology.

"It is quite rare to obtain the "fast-track" designation this early in the drug development process and this was achieved through spectacular preclinical data. We are very proud of this achievement and look forward to the future with great hope for patients," said Mr. Paul Lévesque, President and Chief Executive Officer of Theratechnologies.

About TH1902
TH1902 combines Theratechnologies’ proprietary peptide to docetaxel. This peptide-drug conjugate is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology.

The Canadian Cancer Society and the Government of Quebec, through the Consortium Québécois sur la découverte du médicament (CQDM), contributes a total of 1.4 million dollars towards some of the research currently being conducted for the development of Theratechnologies’ targeted oncology platform.

About Theratechnologies
Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov .

For media and investor inquiries:
Philippe Dubuc
Senior Vice President and Chief Financial Officer
514 336-7800
communications@theratech.com

FAQ

What award did Theratechnologies win in 2021?

Theratechnologies won the 2021 Innovation Award in the Life Sciences category at the ADRIQ Innovation Awards Gala.

What is TH1902 and why is it important for Theratechnologies?

TH1902 is a peptide-drug conjugate that received FDA Fast-track designation, indicating its potential for treating advanced solid tumors.

How much funding is Theratechnologies receiving for its oncology research?

Theratechnologies is receiving a total of $1.4 million from the Canadian Cancer Society and the Government of Quebec for its research.

When did Theratechnologies receive the FDA Fast-track designation for TH1902?

Theratechnologies received the FDA Fast-track designation for TH1902 at the beginning of 2021.